This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Best Growth Stocks to Buy for January 31st
by Zacks Equity Research
PFE, TOL, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 31, 2022
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and J&J
by Zacks Equity Research
Pfizer, BioNTech, Moderna and J&J are included in this analyst blog.
Pfizer (PFE) Gets CHMP Recommendation for COVID Pill Paxlovid
by Zacks Equity Research
Pfizer's (PFE) oral COVID-19 drug, Paxlovid, gets recommendation from the CHMP for its authorization in Europe for treating mild-to-moderate COVID-19 in patients at increased risk of hospitalizations.
Merck (MRK) Keytruda Gets EU Nod for Expanded Kidney Cancer Use
by Zacks Equity Research
Following EU nod, Merck's (MRK) Keytruda is now approved as an adjuvant therapy for renal cell carcinoma in certain adult patients who are at an increased risk of recurrence, following nephrectomy.
Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) fourth-quarter 2021 results.
Pharma Stock Roundup: J&J Q4 Earnings, FDA's Rejection of PFE, MRK Pipeline Drugs
by Kinjel Shah
J&J (JNJ) reports mixed fourth-quarter results. FDA issues CRL to Merck (MRK) and Pfizer's (PFE) pipeline candidates. FDA approves AbbVie's (ABBV) Skyrizi for a second indication.
Best Growth Stocks to Buy for January 28th
by Zacks Equity Research
CROX, M, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 28, 2022
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
Pfizer (PFE), BioNTech Begin Omicron-Based COVID-19 Jab Study
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) announce that the first participants in a clinical study on its Omicron-specific COVID-19 vaccine candidate have been dosed.
Moderna (MRNA) Starts Study for Omicron-Specific Booster Jab
by Zacks Equity Research
Moderna (MRNA) doses the first participant in a phase II study on its Omicron specific COVID-19 booster candidate in a mid-stage study.
Best Growth Stocks to Buy for January 27th
by Zacks Equity Research
TOL, PFE, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 27, 2022
Moderna's (MRNA) Investors Losing Wealth: What Lies Ahead?
by Zacks Equity Research
Moderna's (MRNA) stock has been on a declining trend since August 2021 after a strong rally since the beginning of 2020.
The Zacks Analyst Blog Highlights: Mastercard Inc., Pfizer Inc. and Citigroup Inc
by Zacks Equity Research
Mastercard Inc., Pfizer Inc. and Citigroup Inc are included in this blog.
The Zacks Analyst Blog Highlights: Eli Lilly, Regeneron Pharmaceuticals, Pfizer and Merck
by Zacks Equity Research
Eli Lilly, Regeneron Pharmaceuticals, Pfizer and Merck are included in this blog.
The Zacks Analyst Blog Highlights: Pfizer, Merck, Eli Lilly, Regeneron and Gilead
by Zacks Equity Research
Pfizer, Merck, Eli Lilly, Regeneron and Gilead are included in this analyst blog.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $52.54 in the latest trading session, marking a +1.94% move from the prior day.
The Zacks Analyst Blog Highlights: Roche Holding, Pfizer, Baxter International, STMicro and Philips
by Zacks Equity Research
Roche Holding, Pfizer, Baxter International, STMicro and Philips are included in this analyst blog.
Earnings Season Scorecard and Analyst Reports for Mastercard, Pfizer & Citigroup
by Sheraz Mian
Today's Research Daily features a real-time update on the Q4 earnings season and new research reports on 12 major stocks, including Mastercard Incorporated (MA), Pfizer Inc. (PFE), and Citigroup Inc. (C).
Merck's (MRK) Chronic Cough Drug Gets CRL From FDA
by Zacks Equity Research
Merck's (MRK) new drug application for gefapixant to treat refractory chronic cough or unexplained chronic cough fails to secure approval from the FDA. Meanwhile, the drug secures approval in Japan.
4 Top-Ranked High Earnings Yield Picks to Add to Your Kitty Now
by Rimmi Singhi
Royal Dutch Shell (RDS.A), Goodyear Tire (GT), Pfizer (PFE) and Crocs, Inc. (CROX) could be some attractive bets if you are looking for high earnings yield picks.
FDA Limits Use of Regeneron & Lilly's COVID Antibody Cocktails
by Zacks Equity Research
The FDA modifies EUA for COVID-19 antibody cocktail drugs of Regeneron (REGN) and Lilly (LLY), limiting their use to treat individuals with COVID-19 infection from non-Omicron variants.
J&J (JNJ) Q4 Earnings Beat Estimates by a Penny, Sales Miss
by Zacks Equity Research
J&J (JNJ) reports mixed fourth-quarter results. It beats estimates for earnings but misses the same for sales.
Large Cap Pharma, Biotech Stocks Down on Regulatory Updates
by Zacks Equity Research
Pharma giants like Pfizer (PFE), Merck (MRK) and Eli Lilly (LLY), along with biotech bigwig Regeneron (REGN), are down on regulatory updates.
Best Growth Stocks to Buy for January 25th
by Zacks Equity Research
CROX, M, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 25, 2022
Pfizer's (PFE), OPKO's BLA for Somatrogon Gets CRL From FDA
by Zacks Equity Research
The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.